Subsegment Overview

Genomic Profiling 2026

1.46MB ∙ PDF file

Download

Download

Please download MedTech Monthly Insights - June 2026 below:

Medtech Monthly Insights June 2026 Vf

2.01MB ∙ PDF file

Download

Download

Please download the report on Digital Procedure Technologies below:

Medtech Digital Procedure Technologies Summer 2026

1.21MB ∙ PDF file

Download

Download

Digital Pathology Market Insights 06

1.95MB ∙ PDF file

Download

Download

Subscribe now

Policy and funding risks weigh on near-term visibility

Macro Environment:

•Pharma R&D remains resilient, but spending is modality-specific — Global pharmaceutical R&D spending is projected to reach ~$250B by 2026, with investment concentrated in next-generation modalities such as GLP-1s, ADCs and cell/gene therapies.

•Biotech funding is rebounding, but selectivity remains high — Biotechnology funding surged in 1H26, up approximately 110%-141% versus the same period in 2025, supporting renewed demand for R&D tools while capital remains focused on higher-quality programs.

•Academic funding risk has eased, but growth remains modest — The finalized FY26 NIH budget included a ~1% increase rather than the previously proposed 40% cut, providing stability for academic and government end-markets.

•Policy overhangs are easing, but pricing scrutiny persists — Greater clarity around IRA drug pricing agreements and pharmaceutical tariff policy has improved customer planning visibility, though drug pricing pressure remains a structural constraint.

•Onshoring creates an equipment tailwind, but timing is back-end loaded — Section 232-related pharma onshoring and U.S.-based manufacturing commitments could provide a 10%-20% boost to hardware and equipment demand, with the impact expected to begin in 2027.

•Margin expansion is being driven by cost discipline— Companies are offsetting muted topline growth through opex control and efficiency measures rather than underlying demand strength.

Market Sizing:

Subsegment Overview

Please download Biotech Monthly Insights - June 2026 below:

Biotech Monthly Insights June 2026 Vf

1020KB ∙ PDF file

Download

Download

Please download LSTD Monthly Insights - May 2026 below:

Lst, Services And Diagnostics Monthly Insights May 2026 Vf

1.82MB ∙ PDF file

Download

Download

Please download HCIT Monthly Insights - May 2026 below:

Hcit Monthly Insights May 2026

1.37MB ∙ PDF file

Download

Download

Please download MedTech Monthly Insights - May 2026 below:

Medtech Monthly Insights May 2026

2.08MB ∙ PDF file

Download

Download

Healthcare Market Insights is intended to track these shifts through the lens of M&A, capital raising, and public market read-throughs.

The objective is to provide structured market research on healthcare sectors where transaction activity, financing patterns, and business model evolution are reshaping competitive positioning.

Why Now

Healthcare capital markets have reset from the 2020–2021 period. Financing activity remains available, but investors are more selective, particularly in early-stage diagnostics and tools. Capital is consolidating around later-stage companies, AI-enabled platforms, and businesses with clearer revenue visibility. M&A activity has also been uneven.

This environment creates a useful opportunity for more disciplined market research.

What Healthcare Market Insights Will Cover

This publication will focus on healthcare sectors where transaction activity and capital formation provide useful signals about market direction.

Core coverage areas will include:

• Life sciences tools / Diagnostics

• Medtech

• Biotech

• HCIT

Audience

Healthcare Market Insights is written for readers who follow healthcare as a market, not only as a scientific or clinical field.

The intended audience includes investors, corporate development teams, founders, operators, and commercial leaders looking for structured views on healthcare subsectors and transaction themes.

The publication will be most useful to readers who care about how healthcare companies are financed, valued, acquired, and scaled.